Zobrazeno 1 - 10
of 46
pro vyhledávání: '"J. P. Kuebler"'
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
IntroductionDismembered laparoscopic pyeloplasty (LP) is a well-accepted treatment modality for ureteropelvic junction obstruction (UPJO) in children. However, its efficacy and safety in infants, particularly neonates, remain uncertain. To address th
Externí odkaz:
https://doaj.org/article/c286a3f3e425482d98d4bf0e60679a02
Autor:
Joel D. Provenzano, J. Phillip Kuebler
Publikováno v:
Case Reports in Hematology, Vol 2013 (2013)
Myeloproliferative disorders are variable disorders, based on the genetic abnormality present and the cell line progenitors that are affected. In this case, we discuss a novel gene translocation in the subset of PDGFRB mutations, first seen with prom
Externí odkaz:
https://doaj.org/article/d7cb57aa654c444684fd20c8dcfad3b6
Autor:
G.B. Weiss, J P Kuebler, Laurence H. Baker, W. Gordon, A Mansouri, Sarah A. Taylor, J D McCracken, John Crowley, Lalitha M. Janaki, P G Giri
Publikováno v:
Journal of Clinical Oncology. 8:892-898
The Southwest Oncology Group (SWOG) has conducted a phase II study to explore the efficacy and toxicity of initial, concurrent use of radiation therapy with cisplatin, etoposide (VP-16), and vincristine in limited-stage small-cell carcinoma of the lu
Autor:
J. Pritchard, T. Patel, T. Moore, L. R. Laufman, J. Jones, D. Colborn, J. Zangmeister, C. H. Spiridonidis, J. P. Kuebler, N. Larrimer, L. Carman, R. Roach, L. Gutterman, M. Segal
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(9)
sColumbus Community Clinical Oncology Program, Columbus. Ohio, USA Summary Background Docetaxel and gemcitabine are active against breast cancer. The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined
Autor:
Marcel E. Conrad, S J Ketchel, Geoffrey R. Weiss, Joth Jacobson, John S. Macdonald, Glenn Mills, Saul E. Rivkin, Sarah Taylor, J P Kuebler
Publikováno v:
Investigational new drugs. 18(2)
Background. Chemotherapeutic treatments containingtopoisomerase I inhibitors have shown antitumor activity against anumber of solid tumors. Responses have been seen in Phase I trialsusing topotecan in ovarian, lung, and esophageal cancer. A phase II
Autor:
J. P. Kuebler, James L. Wade, Luke J. Peppone, Shaker R. Dakhil, Joseph A. Roscoe, Michelle C. Janelsins, Supriya G. Mohile, C. E. Heckler, Gary R. Morrow
Publikováno v:
Journal of Clinical Oncology. 29:9012-9012
9012 Background: Despite the widespread use of first generation serotonin receptor antagonists, dexamethasone (DEX) and a variety of other antiemetic medications, delayed nausea has continued to oc...
Autor:
Balazs Halmos, Gregory A. Otterson, Michael R. Snell, J. P. Kuebler, Afshin Dowlati, Shirish M. Gadgeel, A. T. Stefanski, A. Conrad, Pingfu Fu, Tarek Mekhail, Nathan A. Pennell
Publikováno v:
Journal of Clinical Oncology. 29:TPS211-TPS211
TPS211 Background: EGFR-driven NSCLCs are dependent on the EGFR pathway for proliferation which EGFR TKIs potently block. Progression occurs when resistance to erlotinib develops—through the emerge...
Publikováno v:
Investigational New Drugs. 19:327-328
Publikováno v:
Cancer. 67(12)
The pretreatment characteristics of 265 multiple myeloma patients treated between 1977 and 1983 were evaluated as potential prognostic factors for survival. Patients whose diagnosis was based on bone marrow plasmacytosis (greater than 30%) were notic
Autor:
Jan C. Buckner, Judith S. Kaur, P. J. Novotny, J. P. Kuebler, Paul L. Schaefer, Angelina Tan, P. J. Stella, J. A. Sloan
Publikováno v:
Journal of Clinical Oncology. 26:9515-9515
9515 Background: The significance of baseline QOL as a prognostic factor for survival in oncology clinical trials has been suggested in individual trials. We performed a patient-level meta-analysis...